Journal of Psychopharmacology· 2016Q1
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
- 2,178citations
- Q1SCImago
- 2016year
Short summary
A high dose of psilocybin (22 or 30 mg/70 kg) significantly reduced depression and anxiety in 51 cancer patients with life-threatening diagnoses, with sustained benefits observed in approximately 80% of participants at a 6-month follow-up.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Clinical Psychology
Clinical PsychologyPsychology